Literature DB >> 1741521

Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep.

M D Fratacci1, C G Frostell, T Y Chen, J C Wain, D R Robinson, W M Zapol.   

Abstract

Nitric oxide (NO) has recently been discovered to be an important endothelium-derived relaxing factor and produces profound relaxation of vascular smooth muscle. To learn if NO could be a potent and selective pulmonary vasodilator, NO was inhaled by 16 awake lambs in an attempt to reduce the increase in pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) induced by either the infusion of an exogenous pulmonary vasoconstrictor (the thromboxane analog U46619) or the endogenous release of thromboxane that occurs during the neutralization of heparin anticoagulation by protamine sulfate. Inhaling greater than or equal to 40 ppm of NO during a continuous U46619 infusion returned the PAP to a normal value, without affecting systemic blood pressure or vascular resistance. Pretreatment with the cyclooxygenase inhibitor indomethacin before infusing U46619 did not reduce the pulmonary vasodilatory effect of inhaled NO, and we conclude that the dilatory effect of NO on the lung's circulation is independent of cyclooxygenase products such as prostacyclin. Continuously inhaling NO at 180 ppm did not significantly reduce the mean peak thromboxane B2 concentration at 1 min after protamine injection; however, the mean values of pulmonary hypertension and vasoconstriction at 1 min were markedly reduced below the levels in untreated heparin-protamine reactions. Breathing NO at lower concentrations (40-80 ppm) did not decrease the mean peak PAP and PVR at 1 min after protamine but decreased the PAP and PVR values at 2, 3, and 5 min below those of control heparin-protamine reactions. Intravenous infusion of nitroprusside completely prevented the transient increase of PAP and PVR during the heparin-protamine reaction; however, marked concomitant systemic vasodilation occurred. Inhaled NO is a selective pulmonary vasodilator that can prevent thromboxane-induced pulmonary hypertension during the heparin-protamine reaction in lambs and can do so without causing systemic vasodilation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1741521     DOI: 10.1097/00000542-199112000-00011

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  30 in total

1.  Cerebral blood flow during treatment for pulmonary hypertension.

Authors:  S Kusuda; N Shishida; N Miyagi; M Hirabayashi; T J Kim
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-01       Impact factor: 5.747

2.  Bronchodilator action of inhaled nitric oxide in guinea pigs.

Authors:  P M Dupuy; S A Shore; J M Drazen; C Frostell; W A Hill; W M Zapol
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Gaseous Nitric Oxide and Dinitrosyl Iron Complexes with Thiol-Containing Ligands as Potential Medicines that Can Relieve COVID-19.

Authors:  A F Vanin; A V Pekshev; A B Vagapov; N A Sharapov; V L Lakomkin; A A Abramov; A A Timoshin; V I Kapelko
Journal:  Biophysics (Oxf)       Date:  2021-04-27

Review 4.  The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18-20 March 1995.

Authors:  M P Fink; D Payen
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

5.  Nitric oxide (NO) measurement accuracy.

Authors:  M Nishimura; H Imanaka; A Uchiyama; C Tashiro; D Hess; R M Kacmarek
Journal:  J Clin Monit       Date:  1997-07

Review 6.  Nitric oxide release: part III. Measurement and reporting.

Authors:  Peter N Coneski; Mark H Schoenfisch
Journal:  Chem Soc Rev       Date:  2012-02-24       Impact factor: 54.564

7.  The adventitia may be a barrier specific to nitric oxide in rabbit pulmonary artery.

Authors:  R H Steinhorn; F C Morin; J A Russell
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  Methaemoglobin production in normal adults inhaling low concentrations of nitric oxide.

Authors:  J D Young; O Dyar; L Xiong; S Howell
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

9.  Relief of severe pulmonary hypertension after closure of a large ventricular septal defect using low dose inhaled nitric oxide.

Authors:  M Berner; M Beghetti; B Ricou; J C Rouge; R Prêtre; B Friedli
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Inhaled nitric oxide for avoidance of extracorporeal membrane oxygenation in the treatment of severe persistent pulmonary hypertension of the newborn.

Authors:  W Muller; W Kachel; P Lasch; V Varnholt; S A Konig
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.